Insulin Resistance Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Insulin Resistance Epidemiology Forecast Report Coverage

Expert Market Research's “Insulin Resistance Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of insulin resistance. It projects the future incidence and prevalence rates of insulin resistance cases across various populations. The study covers age, gender, and type as major determinants of the insulin resistance population. The report highlights patterns in the prevalence of insulin resistance over time and projects future trends based on multiple variables.

Insulin Resistance Understanding: Disease Overview

Insulin resistance is a metabolic disorder where body cells respond inadequately to insulin, leading to impaired glucose uptake and elevated blood sugar levels. It is strongly associated with obesity, sedentary lifestyle, and genetic predisposition. Over time, it increases the risk of type 2 diabetes, cardiovascular disease, and metabolic syndrome. Insulin resistance epidemiology shows rising global prevalence, particularly in urban populations. Early-stage cases are often asymptomatic, making detection challenging. It represents a key underlying driver of modern metabolic disorders and a major public health concern worldwide.

Insulin Resistance Epidemiology Perspective

The insulin resistance epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the insulin resistance epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for insulin resistance and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Jhosmer Ballena-Caicedo et al., 2025, global insulin resistance prevalence is estimated at approximately 26.5% worldwide, with slightly higher rates in women than in men and increasing prevalence with advancing age, underscoring its status as a leading metabolic disorder across populations.
• Insulin resistance appears more prevalent in men than women, with 64% of males and 54% of females showing insulin resistance, highlighting notable gender-based differences in metabolic risk profiles.
• According to Andrew M. Freeman et al., 2023, globally, HOMA-IR defined insulin resistance increases with age, emerging during puberty, remaining prevalent in young adults aged 18 to 44 years at approximately 40% in US NHANES-based data, and rising further in middle-aged and older populations, reflecting cumulative metabolic and lifestyle-related risk accumulation across the lifespan.
• As per Achuth K. S. et al., 2024, among 895 subjects, 14.3% exhibited prediabetic conditions, strongly associated with elevated body mass index, sedentary lifestyle patterns, and low awareness levels, highlighting key epidemiological risk factors for insulin resistance progression.

Read more about this report - Request a Free Sample

Country-wise Insulin Resistance Epidemiology

The insulin resistance epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Insulin resistance represents a significant and growing metabolic concern across the regions. According to the Iowa Department of Public Health, approximately 84.1 million adults in the United States have prediabetes, with 7.2% of adults in Iowa affected as per the 2017 Behavioral Risk Factor Surveillance System survey, and 15–30% likely to progress to type 2 diabetes within five years if untreated. Similarly, as per Anshul Mamgai et al., 2025, India has an estimated 74.2 million individuals with diabetes and around 255 million with prediabetes, highlighting a significant at-risk population.

Insulin Resistance: Treatment Overview

Insulin resistance treatment focuses on improving insulin sensitivity and preventing progression to type 2 diabetes. First-line interventions include lifestyle modification, such as weight loss, a balanced diet, and regular physical activity. Pharmacological options like metformin are commonly used in high-risk patients to enhance glucose utilization. Emerging therapies target metabolic pathways and inflammation to improve outcomes. Metabolic disorder management emphasizes long-term prevention strategies, including cardiovascular risk reduction. Continuous monitoring of glucose levels and early intervention are critical in reducing disease progression and associated complications.

Key Questions Answered

• What are the key findings of insulin resistance epidemiology in the 8 major markets?
• What will be the total number of patients with insulin resistance across the 8 major markets during the forecast period?
• What was the country-wise insulin resistance epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of insulin resistance patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of insulin resistance during the forecast period of 2026-2035?
• What are the currently available treatments for insulin resistance?
• What are the disease risks, signs, symptoms, and unmet needs of insulin resistance?

Scope of the Insulin Resistance Epidemiology Report

The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of insulin resistance based on several factors.
Insulin Resistance Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
The insulin resistance report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Insulin Resistance Market

Human Insulin Market